 | | Comparative analysis of national drug policies: Second workshop, Geneva, 10-13 June 1996 (WHO/DAP, 1997, 175 p.) |
| | Essential Drugs in Brief No. 1 - 2000 (WHO/DAP - WHO/EDM, 2000, 4 p.) |
| | Essential Drugs in Brief No. 3 - 2001 (WHO/DAP - WHO/EDM, 2001, 4 p.) |
| | Essential Drugs Monitor No. 24 - 1997 (WHO/DAP - WHO/EDM, 1997, 28 p.) |
| | Essential Drugs Monitor No. 25 & 26 - 1998 (WHO/DAP - WHO/EDM, 1998, 36 p.) |
| | Essential Drugs Monitor No. 27 - 1999 (WHO/DAP - WHO/EDM, 1999, 28 p.) |
| | Injection practices in the developing world: A comparative review of field studies in Uganda and Indonesia (WHO/DAP, 1996, 149 p.) |
| | International strategies for tropical disease treatments: Experiences with praziquantel (WHO/DAP, 1998, 113 p.) |
| | The new emergency health kit 98: Drugs and medical supplies for 10,000 people for approximately 3 months (COE - ICRC - IDA - IFRC - MSF - Oxfam - UNICEF - UNFPA - WHO/DAP, 1998, 82 p.) |
| | Producing national drug and therapeutic information: The Malawi approach to developing standard treatment guidelines (WHO/DAP, 1994, 49 p.) |
| | Public education in rational drug use: A global survey (WHO/DAP, 1997, 97 p.) |
| | Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use (WHO/DAP, 1997, 115 p.) |
| | Selected topics in health reform and drug financing (WHO/DAP, 1998, 49 p.) |
| | Use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (WHO/DAP, 1995, 156 p.) |
